Home > About TEDA > Key Industries Brief > Biological Pharmaceutic Industry  
Key Industries Brief
 
  Biological Pharmaceutic Industry
 

Tianjin has had a good foundation for the development in respect of the R&D and industrialization of its biotechnology, biomedicine and modern Chinese medicine: for the first time in the world it has isolated, identified, and prepared a new human stem cell factor hemangiopoietin, developed a number of innovative drugs that have entered clinical study like anti-AIDS membrane fusion inhibitors, and bred the first cloned Boer goat, having obvious advantages in the fields of stem cells, biochips, bio-medicine, etc. Among the existing more than 100 biomedical companies in Tianjin, three rank among the top 10 Chinese pharmaceutical enterprises. This ratio has reached 42% in Binhai New Area. There have been more than 500 domestic enterprises and research institutions engaged in the production of biotechnology-related products, with the annual sale revenue of 30 billion yuan in their biotechnology industry, and a large number of technologies and products with independent intellectual property rights.

Within 26 years,a bio-pharmaceutical chain comprises R&D, technology conversion,production, logistice,showcase and exchange has initially taken shape in TEDA,a region striving to build international competitiveness in life science.Bio-pharmaceutical firms like Novozymes,Novo Nordisk,and GSK,CROs like Asymchem Laboratories and Wuxi AppTec,TCM suppliers like Zhongxin Pharmaceutical and Jinyao Group,medical device suppliers like Siemens and Hanaco are all gathering here and growing healthily.TEDA in biological pharmacy, modern R & D and industrialization of Chinese medicine has a good foundation for development have, in stem cell technologies and therapies in the areas of technology leading in the fields of medical equipment has obvious advantages.

I. Current Situation of the Industry

1. Industrial Convergence

There are 120 bio-pharmaceutical enterprises, 50 foreign-funded enterprises and 70 domestic-funded enterprises, forming a convergence characteristic with foreign-funded enterprises playing the major role in manufacturing and domestic-funded enterprises in scientific and technological innovation.

 

2. Industrial Scale

2011, Biomedical industry output value of 12.240 billion yuan, An increase of 39.1% , accounting for 2.0% of total industrial output value.

3. Industrial Orientation

CRO: Medicinal Chemistry, Active Filtration, Technics, Pharmacology, Safety Assessment, Clinical Medicine
Pharmaceutical Equipment: Diagnostic Reagents, Testing Equipment, Interventional Treatment
Chemical Drugs: Characterized Raw Material Medicine, Generic Drugs
Biopharmaceuticals: Culture of Mammalian Cells (CMO), Monoclonal Antibody
Herbal Medicine: Plant Extraction, Compound Preparations

Focused Areas:
CRO Areas: Compound Screening, Pharmacology, Pharmacodynamics, Pharmacokinetics, Drug Toxicity, Animal Testing, Study of Drug Forms, etc.
Medical Devices: Diagnostic Reagents, Test Instrument, Interventional Therapy, Bone Equipment and others.
CMO Areas: Contract Manufacturing for High Value-added API and Generic Drugs, Large-scale Mammalian-Cell-Culture-Based Bio-pharmaceutical Production Base.

 

4. Leading Enterprises

 

5. TEDA's Industry-Leading Biomedical Enterprises

Name of the Enterprise

Main Products

Ranking

Tianjin Jin Yao Group Co., Ltd

Corticosteroids(Dexamethasone)

The First in the Country

Tianjin Zhongwei Pharmaceutical Co.,

VB1

The First in the Country

Novozymes

Enzyme Preparations

The First in the Country

Tianjin Jianfeng Natural Product Co., Ltd

Cyanine

The First in the Country

WuXi AppTec

Pharmaceutical R & D and Outsourcing

The First in the Country

Newscen Coast Bio-Pharmaceutical Co., Ltd.

AIDS Diagnostic Reagents

First obtained the name of the medicine in the country

 

6. Investment in R & D

TEDA has altogether invested over 200 million yuan into its bio-pharmaceutical inovation system.Today,it is home to 4 state-level R & D centers, 5 enterprise-owned technology centers, and 12 enterprise-owned engineering centers, and boasts 167 bio-pharmaceutical patents.

II. Advantages of TEDA

Location and Market Advantages:

TEDA is located in the heart of the Bohai Sea Economic Circle, adjacent to the port, close to the two major municipalities of Tianjin and Beijing. It has a population of more than 20 million, and its pharmaceutical sales accounts for one fifth of the nation.

Talent Advantages:

There are 200 tertiary institutions within the 150-km city circle of Beijing-Tianjin. Every year, there are more than 5000 graduates majored in chemistry, biology, medicine and other related majors, nearly 200,000 personnel engaged in related scientific researches, and more than 2 million industrial workers.

R & D Advantages:

Tianjin has such a number of research institutions as Tianjin Industrial Biotechnology R & D Center, Chinese Academy of Sciences (TIBC, CAS), and Tianjin Institute of Pharmaceutical Research (TIPR). In the Tenth Five-Year Period, it obtained a total of more than 300 certificates for various types of new drugs. Beijing has 31.9% national laboratories of key disciplines in medical category, and state key laboratories of life sciences which account for 41% of the country.

 

Clinical Advantages:

Tianjin and Beijing have 60 A-level hospitals, and a number of clinical bases confirmed by the State Food and Drug Administration (SFDA), involving many fields like cardiovascular diseases, blood, tumor, surgery, geriatrics, infectious diseases.

Policy Advantages: With an annual budget of 200 million yuan,the TEDA Bio-pharmaceutical Industry Fund provides support to the industry in terms of land,facility,equipment,funding,tax incentive,and talent.Subsidies are issued to facilitate independent R&D,project funding,market access,and patent fees.As a special economic zone directly under the Central Government,TEDA is authorized to carry out pilot reform in the streamlining of new drug approval procedure,sample testing,customs inspection and quarantine,tariff exemption for equipment imports.

Advantages of Government Services: It provides professional services, including: expert advice, public facilities, financing, academic exchanges, patent agency, vocational training and so on. It set up an expert advisory committee, invested nearly 70 million yuan in public equipment, and established Regional Equipment-Sharing Networks, Bole (China) Life Science Venture Capital Funds and other 3 financial institutions.

[1] [2] [3]  

TIANJIN SHIN POONG PHARMACEUTICAL
SERVIER (TIANJIN ) PHARMACEUTICAL
NOVO NORDISK (TIANJIN) BIOTECHNOLOGY
TIANJIN NEWSCEN COAST BIO-PHARMACEUTICAL
TIANJIN CENWAY CHEMICALS
TIANJIN JIANFENG NATURAL PRODUCT R&D
TIANJIN BIOPHARMICA
HNOVOZYMES (CHINA) BIOTECHNOLOGY
CHIRACHEM LABORATORIES (TIANJIN)
TIANJIN DEPU BIO-TECHNOLOGICAL & MEDICAL PRODUCTS INC
TIANJIN TEDA BIOMEDICAL ENGINEERING
TIANJIN HUALIDA BIOLOGCAL ENGINEERING
TIANJIN TEDA PHARMACEUTICAL
TIANJIN GRANDSBERG PHARMACEUTICAL
TIANJIN TIAN AN PHARMACEUTICAL HOLDING COMPANY
TIANJIN ZENYAKU ANIMAL HEALTH
TIANJIN TANABE SEIYAKU
GLAXOSMITHKLINE (TIANJIN)